Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Serum phosphate level greater than (\>) 5.5 milligram per deciliter (mg/dL) (1.78 millimole per liter \[mmol/L\]) after discontinuation of current phosphate binder therapy~* Men or women 18 years or older~Exclusion Criteria:~* Have active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
- Genz-644470 2.4 Grams Per Day (g/day) (Type: EXPERIMENTAL): Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
- Genz-644470 4.8 g/day (Type: EXPERIMENTAL): Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
- Genz-644470 7.2 g/day (Type: EXPERIMENTAL): Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
- Sevelamer Carbonate 2.4 g/day (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
- Sevelamer Carbonate 4.8 g/day (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
- Sevelamer Carbonate 7.2 g/day (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).